Live Friday, Jul 24, 2026 | 11am PST
Overview
GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have transformed the treatment of obesity and Type 2 diabetes. 29 million American adults are currently using a GLP-1 medication. Pediatric prescriptions for GLP-1s have jumped by 700%.
As their popularity surges, researchers are raising questions and concerns. How long should patients remain on these medications? What happens when they stop taking them? Are there unintended consequences for developing bodies or aging muscles and bones? And who has access to these costly treatments?
Speakers this Friday will examine the growing public health implications of medications that are reshaping the way obesity and chronic disease are treated in the United States.
Related Coverage
- GLP-1 Drugs Show Promise, But Researchers Question Lifelong Use, Prescriptions for Children, and Cost Barriers
- YOUTUBE PLAYLIST: Beyond Weight Loss: Examining the Promise and Risks of GLP-1 Drugs Across the Lifespan
Guest Speakers
- Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics, Harvard Medical School
- Dr. Dan Cooper, Distinguished Professor, Emeritus, Pediatrics, UC Irvine
- Jasmyne Cannick, race, politics, and social issues commentator and award- winning journalist
- Dr. Jena Shaw Tronieri, Senior Research Investigator, Center for Weight and Eating Disorders, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania
Hi,
Great article I’ve found that combining the right guidance with GLP-1 support after bariatric surgery can really make a difference. I’ve personally been using the resources at https://rolandmedicalweightloss.com/ and found them very helpful for understanding long-term weight management.